• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Avenue Therapeutics Inc.

    7/12/24 4:09:03 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATXI alert in real time by email
    S-8 1 atxi20240702_s8.htm FORM S-8 atxi20240702_s8.htm

    As filed with the Securities and Exchange Commission on July 12, 2024

    Registration No. 333-________



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     


    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     


     

    Avenue Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware  

     

    47-4113275  

    (State or other jurisdiction of
    incorporation or organization)  

      

    (I.R.S. Employer
    Identification No.)  

         

    1111 Kane Concourse, Suite 301
    Bay Harbor Islands, Florida 33154

     

    33154  

    (Address of Principal Executive Offices)  

      

    (Zip Code)  

     

     

    Avenue Therapeutics, Inc. 2015 Incentive Plan, as Amended

    (Full title of the plan)

     

    Alexandra MacLean, M.D.

    Chief Executive Officer

    1111 Kane Concourse, Suite 301
    Bay Harbor Islands, Florida 33154

    (781) 652-4500

    (Name, address, and telephone number of agent for service)

     

    Copy to:

    Rakesh Gopalan

    David S. Wolpa

    Troutman Pepper Hamilton Sanders LLP

    301 S. College Street, 34th Floor

    Charlotte, North Carolina 28202

    (704) 998-4050

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b2 of the Exchange Act. (Check one):

     

    Large accelerated filer ☐

    Accelerated filer ☐

    Non-accelerated filer ☒

    Smaller reporting company ☒
    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     



     

     

     


     

     

     

    INCORPORATION BY REFERENCE OF CONTENTS

    OF REGISTRATION STATEMENT ON FORM S-8

     

    This Registration Statement is being filed by Avenue Therapeutics, Inc. (the “Registrant”) for the purpose of registering the offer and sale of an additional 5,000,000 shares of common stock, $0.0001 par value per share (the “Common Stock”), that are issuable pursuant to the Registrant’s 2015 Incentive Plan, as amended (the “Plan”). These additional shares of Common Stock are securities of the same class as other securities for which a Registration Statement on Form S-8 of the Registrant relating to the same stock incentive plan is effective. The Registrant previously registered the offer and sale of shares of Common Stock issuable under the Plan under a Registration Statement on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on August 15, 2017 (File No. 333-219972), as amended by a Registration Statement on Form S-8, filed with the Commission on December 17, 2021 (File No. 333-261710), and a Registration Statement on Form S-8 filed with the Commission on February 10, 2023 (File No. 333-269689). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.

     


     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits

     

    The Exhibits listed on the Exhibit Index of this Registration Statement are filed herewith or are incorporated by reference to other filings.

     

    EXHIBIT INDEX

     

    Exhibit

       
    Number   Description
         

    4.1

      Third Amended and Restated Certificate of Incorporation of Avenue Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38114) filed with the Commission on June 27, 2017).
    4.2   Certificate of Amendment of the Third Amended and Restated Certificate of Incorporation of Avenue Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38114) filed with the Commission on August 14, 2018).
    4.3   Certificate of Amendment of the Third Amended and Restated Certificate of Incorporation of Avenue Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38114) filed with the Commission on February 3, 2023).
    4.4   Certificate of Amendment of the Third Amended and Restated Certificate of Incorporation of Avenue Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38114) filed with the Commission on February 23, 2024).
    4.5   Certificate of Amendment of the Third Amended and Restated Certificate of Incorporation of Avenue Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38114) filed with the Commission on April 26, 2024).
    4.6   Second Amended and Restated Bylaws of Avenue Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38114) filed with the Commission on February 10, 2023).
    5.1*   Opinion of Troutman Pepper Hamilton Sanders LLP
    23.1*   Consent of KPMG LLP
    23.2*   Consent of Troutman Pepper Hamilton Sanders LLP (included in Exhibit 5.1 to this Registration Statement on Form S-8)
    24.1*   Powers of Attorney (included on signature pages to this registration statement)

    99.1

      Avenue Therapeutics, Inc. 2015 Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registrant’s Form 10-12G (File No. 000-55556) filed with the Commission on January 12, 2017).
    99.2   Amendment to the Avenue Therapeutics, Inc. 2015 Incentive Plan (incorporated by reference to Exhibit 99.2 to the Registrant’s Form S-8 (File No. 333-261710) filed with the Commission on December 17, 2021).
    99.3   Amendment to the Avenue Therapeutics, Inc. 2015 Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K  (file No. 001-38114) filed with the Commission on February 3, 2023).
    99.4   Amendment to the Avenue Therapeutics, Inc. 2015 Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K   (file No. 001-38114) filed with the Commission on June 26, 2024).
    107.*   

    Filing Fee Table

     

    *Filed herewith


     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bay Harbor Islands, State of Florida, on this 12th day of July, 2024.

     

    Avenue Therapeutics, Inc.
     
    By: /s/ Alexandra MacLean, M.D.
      Name: Alexandra MacLean, M.D.
      Title: Chief Executive Officer

     

    POWERS OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below hereby constitutes and appoints each of Alexandra MacLean, M.D. and David Jin, as his or her true and lawful attorney-in-fact and agent, with power to act without any other and with full and several power of substitution, for him or her and in his or her name, place and stead, to sign, in his or her capacity or capacities as shown below, any and all amendments to this Registration Statement on Form S-8 (including post-effective amendments), and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection with any such amendments, as fully for all intents and purposes as he or she might or could do in person, and does hereby ratify and confirm all that said attorneys-in-fact and agents, or either of them, or their substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

     

    Signature   Date   Title
             
    /s/ Alexandra MacLean, M.D.   July 12, 2024   Chief Executive Officer
    Alexandra MacLean, M.D.       (Principle Executive Officer)
             
    /s/ David Jin   July 12, 2024   Interim Chief Financial Officer and Chief Operating Officer
    David Jin       (Principal Financial and Accounting Officer)
             
    /s/ Lindsay A. Rosenwald, M.D.   July 12, 2024   Executive Chairman of the Board
    Lindsay A. Rosenwald, M.D.        
             
    /s/ Faith Charles   July 12, 2024   Director
    Faith Charles        
             
    /s/ Neil Herskowitz   July 12, 2024   Director
    Neil Herskowitz        
             
    /s/ Jay Kranzler, M.D., PhD   July 12, 2024   Director
    Jay Kranzler, M.D., PhD        
             
    /s/ Curtis Oltmans   July 12, 2024   Director
    Curtis Oltmans        

     

     
    Get the next $ATXI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATXI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ATXI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Avenue Therapeutics Inc.

    SCHEDULE 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

    1/6/26 4:11:21 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avenue Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)

    12/31/25 9:20:53 AM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Avenue Therapeutics Inc.

    EFFECT - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)

    12/17/25 12:15:12 AM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kranzler Jay D bought $1,250 worth of shares (500 units at $2.50), increasing direct ownership by 417% to 620 units (SEC Form 4)

    4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)

    10/1/24 4:15:13 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ATXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

    MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the third quarter ended September 30, 2024. "We have generated considerable momentum this past quarter in advancing our pipeline of innovative treatments for neurologic diseases," said Alexandra MacLean, M.D., Chief Executive Officer of Avenue. "AJ201 is a potential best-in-class asset that would bring a disease-modifying therapeutic option to patients with significant unmet m

    11/14/24 4:05:03 PM ET
    $ATXI
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit

    MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in a fireside chat at Maxim Group's 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 1:30 PM ET. The fireside chat will be available to registered attendees. Investors may sign-up or log-in to the conference here. About Avenue TherapeuticsAvenue Therapeutics, Inc. (NASDAQ:ATXI) is a specialty pharmaceutical company focus

    10/9/24 8:30:59 AM ET
    $ATXI
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avenue Therapeutics to Participate in Upcoming Investor Conferences

    MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in the following upcoming investor conferences: H.C. Wainwright 26th Annual Global Investment ConferenceDate: Monday, September 9, 2024Location: New YorkFormat: Company Presentation and 1x1 Meetings Lake Street Capital Markets BIG8 ConferenceDate: Thursday, September 12, 2024Location: New YorkFormat: 1x1 Meetings The H.C. Wainwright

    9/3/24 8:30:35 AM ET
    $ATXI
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Fortress Biotech, Inc. was granted 111,209 shares, increasing direct ownership by 34% to 439,733 units (SEC Form 4)

    4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)

    1/6/26 4:05:23 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Fortress Biotech, Inc. was granted 33,724 shares, increasing direct ownership by 11% to 328,524 units (SEC Form 4)

    4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)

    4/2/25 4:05:13 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Fortress Biotech, Inc. claimed ownership of 294,800 shares (SEC Form 3)

    3 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)

    1/3/25 4:21:27 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Avenue Therapeutics Inc.

    SC 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

    11/15/24 4:05:50 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Avenue Therapeutics Inc.

    SC 13G - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

    11/14/24 3:22:45 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Avenue Therapeutics Inc. (Amendment)

    SC 13G/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

    5/2/24 4:02:02 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXI
    Leadership Updates

    Live Leadership Updates

    View All

    Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer

    MIAMI, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company") (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary company focused on the development and commercialization of pharmaceutical products to treat gout and chronic kidney disease, today announced the appointments of Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer and Vibeke Strand, M.D., MACR, FACP, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University, to its Board of Directors. Lindsay A. Rosenwald, M.D., Fortress' Chairman and Chief Executive Officer and Board Member of Urica, said, "We ar

    10/3/22 8:00:00 AM ET
    $ATXI
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXI
    Financials

    Live finance-specific insights

    View All

    Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

    MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will host a virtual key opinion leader ("KOL") event highlighting expert perspectives on spinal bulbar muscular atrophy ("SBMA"), also known as Kennedy's Disease, on Thursday, April 4, 2024 at 11:00am ET. The virtual event will focus on the potential of AJ201 in SBMA, including KOL perspectives on the SBMA treatment landscape, an overview of the Phase 1b/2a study evaluating AJ201 for the treatment of SBMA and outcome co

    3/25/24 8:30:00 AM ET
    $ATXI
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

    Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023 Positive topline results from two Phase 3 clinical trials evaluating DFD-29 demonstrated achievement of co-primary and all secondary endpoints versus placebo and Oracea® (doxycycline) with no significant safety issues Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in the second half of 2023 for DFD-29 and CUTX-101 Cosibelimab longer-term results demonstrated substantial increases in complete response rates in advanced cutaneous squamous cell carcinoma PDUFA goal date of January 3, 2024, set by FDA for cosi

    8/14/23 4:01:50 PM ET
    $ATXI
    $CKPT
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care